Biocompatible ocular implants

• US 5,766,242 A
• Filed: 03/13/1996
• Issued: 06/16/1998
• Est. Priority Date: 11/15/1993
• Status: Expired due to Term

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Oculex Pharmaceuticals, Inc. (Abbvie Incorporated)
• Inventors: Wong, Vernon G., Kochinke, Frank
• Primary Examiner(s): SHAY, RANDY CITRIN
• Application Number:
  US08/615,640
• Time in Patent Office: 825 Days
• Field of Search: 623/4, 623/5, 424/426-429, 604/294, 604/890.1, 604/891.1, 604/892.1
• US Class Current: 128/898
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Claims

1. A method for treating an eye condition which comprises:

preparing a non-biodegradable physiologically acceptable implant comprising a physiologically active therapeutic agent and a membrane layer for controlling the diffusion of said therapeutic agent from said polymer;

introducing said implant extrinsic to the vitreous such that the membrane layer is positioned intermediate to said polymer and said site of said eye condition, and is incapable of migration from an implantation site, wherein said site comprises the suprachoroidal space and a surgically induced avascular region of the choroid, permitting diffusion of a physiologically active agent from said implant into the vitreous, and in proximity to said eye condition;

wherein said therapeutic agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time.

2. The method of claim 1, wherein said implant further comprises a backing layer for preventing diffusion of said therapeutic agent away from said site of said eye condition and said introducing step further comprises positioning said backing layer distal to said site of said eye condition.

3. The method of claim 1, wherein said preparing step comprises preparing said implant from a polyurethane polymer.

4. The method of claim 1, wherein said preparing step comprises preparing said implant from an ethylene vinyl ester copolymer.

5. The method of claim 1, wherein said preparing step comprises preparing said implant from ethylene vinyl acetate.